MEDRIX DOCTEUR THOMAS FERRANT

Active

Private limited companyfounded 2014active for 12 yearsDrève aux Silex 4, 1495 Villers-la-Ville, BelgiumKBO/BCE: BE 0550.608.325

From the official registers: KBO 12 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

MEDRIX DOCTEUR THOMAS FERRANT has been active since 2014 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €135,502 and a net result of €304,099. Equity has been growing by about 19% per year since 2018. Its solvency ranks better than 24% of 3,024 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow Report Compare

MEDRIX DOCTEUR THOMAS FERRANTActiveChecked score 94/100

Risk analysis Report Compare

Official details

KBO

Status: Active since 31-03-2014 Normal situation
Legal form: Private limited company
Registered office: Drève aux Silex 4, 1495 Villers-la-Ville
Activity: Specialist medical practice NACE 86220
Establishment unit: 2.229.793.834 1495 Villers-la-Ville, since 14-04-2014
Financial year end: 31 December
Peppol: Reachable since 05-03-2026

Company details

Board and ownership

Board

PEJ-FERRANTDirector · since 02-12-2022 · permanent representative Thomas FERRANT
Thomas FERRANTDirector · since 02-12-2022

Board & ownership

Financial position

94 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: < 0.1%

Annual accounts 2025

Gross margin: €357,618; ▲ 6.2%
Turnover: ≈ €700,000; estimated
Profit: €304,099; ▲ 9.8%
Equity: €135,502; ▲ 33.6%
Total assets: €552,125; ▲ 15.0%

2025 accounts filed 11 days after the deadline

Filed on 11-08-2026at the National Bank

Financials

Score breakdownlowers riskSector: Human health activities (NACE 86)Size: total assets €552,125Figures for financial year 2025 (filed on 15-08-2026)Liquidity: current ratio 1.15, cash €219,449Show the evidence

Checked score

Score 2025

94 / 100

Excellent

Probability in this band: under 0.55%

Financially stronger than 53% of micro companies in human health (NACE 86)

Every signal that counts is listed under Signals.

Financial strength · tick: 2024

Strong

Solvency 50+4

equity 24.5% of total assets

Liquidity 59+13

short-term debt 75.5% · cash 39.7%

Profitability 100=

return on assets 55.1%

Bankruptcy probability within 12 months

< 0.1% Very low

0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,155 companies, NACE 86, micro)

Last 24 months 11-2024: < 0.1% 12-2024: < 0.1%● unchanged vs 11-2024 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: 0.1%▲ +0.1 percentage points vs 07-2025 09-2025: < 0.1%▼ -0.1 percentage points vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: 0.1%▲ +0.1 percentage points vs 07-2026highest value 09-2026: < 0.1%▼ -0.1 percentage points vs 08-2026lowest value 10-2026: < 0.1%● unchanged vs 09-2026lowest value

Credit of up to €12,000 on 30-day terms is acceptable

Liquidity is tight, with a current ratio of 1.15 (1.21 in 2024), below the usual 1.5. Short-term debt is 75.5% and cash 39.7% of total assets. 75.5% of the assets are financed with debt and provisions.

Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 23% of them on solvency, 36% on liquidity, 80% on profitability and 74% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.

lowers riskraises risk

Sector: Human health activities (NACE 86)

KBO

Size: total assets €552,125

Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.

NBB · annual accounts

Figures for financial year 2025 (filed on 15-08-2026)

NBB · annual accounts

Liquidity: current ratio 1.15, cash €219,449

NBB · annual accounts

Weak solvency compared with the sector

Solvency (equity / total assets) is in the sector's weakest quartile: better than 24% of 3024 sector peers (2025).

NBB · sector comparison

Position among 3024 sector peers

Solvency

better than 24%

← weakest strongest →

2025 accounts filed 11 days late

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 11-08-2026, 11 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.

NBB · 10 filings

Deviation from the deadline

2025

11 days late

2024

27 days late

2023

22 days late

2022

10 days late

2021

26 days early

2020

20 days late

2019

91 days late

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 22 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 11 August (4 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

01-11-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

That holds for every publication since 2021.

KBO publications

Key points

Positive: 8th largest company by total assets in Villers-la-Ville, Health and social work…in the Checked rankings No. 8 View
Positive: 8 profitable years in a rowprofit 2025: €304,099 8 years View

Documents

Key facts about MEDRIX DOCTEUR THOMAS FERRANT

What is the company number of MEDRIX DOCTEUR THOMAS FERRANT?: The company number of MEDRIX DOCTEUR THOMAS FERRANT is 0550.608.325. The VAT number is the same number with BE in front: BE 0550.608.325.
Where is MEDRIX DOCTEUR THOMAS FERRANT based?: The registered office is at Drève aux Silex 4, 1495 Villers-la-Ville.Company details
What does MEDRIX DOCTEUR THOMAS FERRANT do?: According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of MEDRIX DOCTEUR THOMAS FERRANT?: The legal form of MEDRIX DOCTEUR THOMAS FERRANT is Private limited company (BV).
When was MEDRIX DOCTEUR THOMAS FERRANT founded?: MEDRIX DOCTEUR THOMAS FERRANT was founded on 31-03-2014.
Is MEDRIX DOCTEUR THOMAS FERRANT still active?: Yes, MEDRIX DOCTEUR THOMAS FERRANT is an active enterprise in the KBO register.
What is the turnover of MEDRIX DOCTEUR THOMAS FERRANT?: The turnover in financial year 2025 is ≈ €700,000. This figure is estimated from the gross margin of €357,618 and 40 comparable companies (NACE 862). It probably lies between €470,000 and €1.1m.Financials
Is MEDRIX DOCTEUR THOMAS FERRANT profitable?: In financial year 2025, MEDRIX DOCTEUR THOMAS FERRANT made a profit of €304,099.
Where can I find the annual accounts of MEDRIX DOCTEUR THOMAS FERRANT?: MEDRIX DOCTEUR THOMAS FERRANT filed 12 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
When are the next annual accounts of MEDRIX DOCTEUR THOMAS FERRANT due?: MEDRIX DOCTEUR THOMAS FERRANT must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Comparable companies

These companies have the same main activity as MEDRIX DOCTEUR THOMAS FERRANT: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €491,000 and €567,000, founded between 2013 and 2014.

Company	Total assets	Gross margin
MEDRIX DOCTEUR THOMAS FERRANT Villers-la-Ville	€552,125	€357,618
DR. WOUTER DE CORTE, ANESTHESIST Zulte	€550,616	€358,630
MCWijnegem Dental Wijnegem	€521,349	€372,268
DR. BOUCKAERT BERNARD Roeselare	€566,533	€387,710
CABINET DE GYNECOLOGIE ANTON DANIEL Arlon	€493,204	€364,120
CARD-EP Beersel	€492,387	€349,644
Dr. Charlotte Cools, Anesthesie en reanimatie Puurs-Sint-Amands	€490,595	€371,091